Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies

被引:17
|
作者
Hager, ACM [1 ]
Ellmark, P [1 ]
Borrebaeck, CAK [1 ]
Furebring, C [1 ]
机构
[1] Lund Univ, Dept Immunotechnol, S-22007 Lund, Sweden
关键词
D O I
10.1046/j.1365-3083.2003.01271.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and interfering antibodies have been suggested as an effective approach for the treatment of lymphomas and autoimmune diseases. In this study we have profiled a panel of mouse antihuman CD40 monoclonal antibodies (MoAbs), regarding their CD40 binding affinity and epitope-specificity relative to the CD40L binding in relation to their cellular activating potential. Despite a rather similar domain-recognition profile, the MoAbs blocked the CD40L binding to a varying degree, with MoAb 5C3 being the poorest inhibitor. There was no correlation between affinity and cellular activation potential. In contrast, a correlation between the ability to block CD40L-binding and activation potential could be seen. We believe that this analysis of several mouse anti-CD40 antibodies can be used to develop strategies for producing new human anti-CD40 antibodies that can more effectively induce or block B-cell proliferation.
引用
收藏
页码:517 / 524
页数:8
相关论文
共 50 条
  • [31] Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis
    Tanaka, H.
    Yang, G. -X.
    Iwakoshi, N.
    Knechtle, S. J.
    Kawata, K.
    Tsuneyama, K.
    Leung, P.
    Coppel, R. L.
    Ansari, A. A.
    Joh, T.
    Bowlus, C.
    Gershwin, M. E.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 174 (03): : 364 - 371
  • [32] PROPERTIES OF MOUSE CD40 - CELLULAR-DISTRIBUTION OF CD40 AND B-CELL ACTIVATION BY MONOCLONAL ANTI-MOUSE CD40 ANTIBODIES
    HASBOLD, J
    JOHNSONLEGER, C
    ATKINS, CJ
    CLARK, EA
    KLAUS, GGB
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (08) : 1835 - 1842
  • [33] The Use of Anti-CD40 mAb in Cancer
    Remer, Marcus
    White, Ann
    Glennie, Martin
    Al-Shamkhani, Aymen
    Johnson, Peter
    CANCER VACCINES, 2017, 405 : 165 - 207
  • [34] Adjuvanticity of anti-CD40 in vaccine development
    Carlring, J
    Barr, T
    Heath, AW
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (01) : 73 - 77
  • [35] Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies
    Mueller, Philipp
    Thommen, Daniela S.
    Zippelius, Alfred
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (08) : 692 - 694
  • [36] TMA Development in Kidney and Heart Xenografts Treated with Anti-CD40 or Anti-CD154 Antibodies.
    Ma, D. H.
    Sasaki, H.
    Ahrens, K.
    Becerra, D.
    Rickert, C. G.
    Detelich, D. M.
    Oura, T.
    Somer, W.
    Rosales, I.
    Pierson, R. N.
    Markmann, J.
    Madsen, J. C.
    Kuwai, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 1054 - 1054
  • [37] Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas
    Funakoshi, S
    Longo, DL
    Murphy, WJ
    JOURNAL OF IMMUNOTHERAPY, 1996, 19 (02): : 93 - 101
  • [38] Anti-CD40 Antibodies do not Cause Thromboembolism as Demonstrated by in Vitro and in Vivo Studies
    Rubic-Schneider, Tina
    Christen, Brigitte
    Garcia, Deborah
    Loll, Nathalie Runser
    Erard, Esther
    Flandre, Thierry
    de Billy, Benjamin Cochin
    Nock, Sebastien
    Cote, Serge
    Rush, James S.
    Ulrich, Peter
    TRANSPLANTATION, 2018, 102 : S715 - S715
  • [39] Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
    Li, Da-Ke
    Wang, Wen
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [40] Purification of monoclonal antibodies by epitope and mimotope affinity chromatography
    Murray, A
    Sekowski, M
    Spencer, DIR
    Denton, G
    Price, MR
    JOURNAL OF CHROMATOGRAPHY A, 1997, 782 (01) : 49 - 54